Aptar Pharma, a manufacturer of drug delivery systems for nasal applications, has installed manufacturing capacity for its Child-Resistant and Senior-Friendly Classic Nasal Pump at its Congers, NY site. 
 
A new assembly machine for its Child-Resistant (CR) feature for nasal sprays was transferred from Aptar’s plant in Southern Germany to Congers, NY. This technology platform was developed primarily for the U.S. market following the 2012 U.S. Consumer Product Safety Commission (CPSC) rule requiring Child-Resistant packaging for any drug product containing 0.08 milligrams or more of imidazoline (16 CFR Part 1700.14), a formulation widely used in nasal decongestant topical sprays. Aptar’s newly-engineered CR/Senior-Friendly nasal spray pump incorporates its squeeze-and-turn technology and meets the CPSC requirements.
 
Alex Theodorakis, president Aptar Pharma North America, said, “We are pleased to welcome the arrival of Aptar Pharma’s Child-Resistant assembly machine to our recently-expanded Congers, NY manufacturing site. This added manufacturing capacity enables us to offer the production of this key Child-Resistant/ Senior-Friendly feature to our customers domestically. Being closer to our customers continues to be of strategic importance to Aptar Pharma, and this new initiative enables us to continue to support our important North American marketplace and increase our demand reactivity.”